Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02067923 · ClinicalTrials.gov registry record
AbATE Follow-Up Study
A clinical trial, sponsored by Yale University.
- Completed
- Registry status
- 44
- Enrollment target
NCT02067923 is a clinical trial that has completed, run by Yale University. The registered enrollment target is 44 participants.
The verdict
NCT02067923 has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- 44 participants
- Enrollment target
Study Summary
This study proposes to conduct a non-interventional, multi-center trial that will look at C-peptide results from one or two Mixed Meal Tolerance Tests (MMTT) in participants who received anti-CD3 treatment or placebo on the Abate ITN027AI trial. Anti-CD3 monoclonal antibody is a humanized antibody that is commonly used to prevent organ rejection. It was give in order to determine whether anti-CD3 mAb treatment can halt the progression of newly diagnosed type 1 diabetes. The overall hypothesis of this study is there will be less change in c-peptide levels of the previously treated group versus the control group.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 2014-02 |
| Est. Completion | 2016-11-17 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02067923
The ClinicalTrials.gov registry entry for NCT02067923 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 44 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT02067923 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02067923 about?
NCT02067923 is a clinical study titled "AbATE Follow-Up Study". This study proposes to conduct a non-interventional, multi-center trial that will look at C-peptide results from one or two Mixed Meal Tolerance Tests (MMTT) in participants who received anti-CD3 treatment or placebo on the Abate ITN027AI trial. Anti-CD3 monoclonal antibody is a humanized antibody t...
What is the current status of trial NCT02067923?
This trial is currently completed. The enrollment target is 44 participants. The study started on 2014-02. Estimated completion is 2016-11-17.
Who is sponsoring clinical trial NCT02067923?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.